Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET

Company Participants

Dan Ferry - LifeSci Advisors
Jon Congleton - Chief Executive Officer
Adam Levy - Chief Financial Officer
David Rodman - Chief Medical Officer

Conference Call Participants

Michael DiFiore - Evercore
Richard Law - Goldman Sachs
Annabel Samimy - Stifel
Rami Katkhuda - LifeSci Capital
Matthew Caufield - H.C. Wainright

Operator

Greetings. Welcome to Mineralys Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce Dan Ferry of LifeSci Advisors. Please begin.

Dan Ferry

Thank you, operator. Good afternoon, everyone and welcome to our third quarter 2024 conference call. After the close of market trading today, we issued a press release providing our third quarter 2024 financial results and business updates. A replay of today's call will be available on the Investors section of our website approximately 1 hour after its completion. After our prepared remarks, we will open the call for Q&A.

Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in today's press release and in our SEC filings, including our annual report on Form 10-K and subsequent filings. Please note that these forward-looking statements reflect our opinions only as of today, November 11. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events.

I would now like to turn the call over to Jon Congleton, Chief Executive Officer of Mineralys Therapeutics. Jon?

Jon Congleton

Thank you, Dan. Good afternoon, everyone and welcome to our third quarter 2024 financial results and corporate update conference call. I'm joined today by Adam Levy, our Chief Financial Officer; and Dr. David Rodman, our Chief Medical Officer. I'll begin with an overview of the business, our clinical programs and recent milestones. Then Adam will review our third quarter financial results before we open up the call for your questions.

I want to kick things off with a recap of the progress the Mineralys team has made these past several months, advancing our pivotal clinical development of lorundrostat in hypertension and then discuss the upcoming milestones we anticipate throughout the first half of 2025. We recently completed enrollment in our pivotal Advance-HTN trial which is evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled or resistant hypertension, when used as an add-on therapy to a standardized background treatment of 2 or 3 antihypertensive medications.